Pubblicazioni

Risk of Getting COVID-19 in People with Multiple Sclerosis A Case-Control Study

2022 - NEUROLOGYÂ® NEUROIMMUNOLOGY & NEUROINFLAMMATION

Iaffaldano, P.; Lucisano, G.; Manni, A.; Paolicelli, D.; Patti, F.; Capobianco, M.; Morra, V. B.; Sola, P.; Pesci, I.; Lus, G.; De Luca, G.; Lugaresi, A.; Cavalla, P.; Montepietra, S.; Maniscalco, G. T.; Granella, F.; Ragonese, P.; Vianello, M.; Brambilla, L.; Totaro, R.; Toscano, S.; Malucchi, S.; Petracca, M.; Moiola, L.; Ferraro, D.; Lepore, V.; Mosconi, P.; Ponzio, M.; Tedeschi, G.; Comi, G.; Battaglia, M. A.; Filippi, M.; Amato, M. P.; Trojano, M.

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)

2016 - MULTIPLE SCLEROSIS

Lanzillo, Roberta; Quarantelli, Mario; Pozzilli, Carlo; Trojano, Maria; Amato, Maria Pia; Marrosu, Maria G.; Francia, Ada; Florio, Ciro; Orefice, Giuseppe; Tedeschi, Gioacchino; Bellantonio, Paolo; Annunziata, Pasquale; Grimaldi, Luigi M.; Comerci, Marco; Brunetti, Arturo; Bonavita, Vincenzo; Alfano, Bruno; Marini, Stefano; Brescia Morra, Vincenzo

Pubblicazioni

Risk of Getting COVID-19 in People with Multiple Sclerosis A Case-Control Study

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)

No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon ÃÂ²1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study)